Rasio cepet: Sight Sciences, Inc. (SGHT)

The GURU.Markets price chart for Sight Sciences, Inc. (SGHT), where the indicator stands at 4.87, highlights the engineering team's success in combating vision loss. Revenues are driven by physicians' preference for efficient microsurgical glaucoma therapy methods. Meanwhile, stringent patents and FDA requirements create a robust defensive barrier, limiting the entry of new players into this narrow niche.

Quick liquidity determines the ability of Sight Sciences, Inc. (SGHT) to settle short-term obligations using its most mobile assets. The calculation excludes inventories, focusing instead on cash and accounts receivable to assess real solvency. An acid-test liquidity analysis reveals the company's financial reserve. This buffer is critical for Sight Sciences, Inc. (SGHT) amid electronics supply chain disruptions and a slowdown in international equipment certification.